1. Fogari R, Zoppi A, Corradi L et al. _-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999;534-9
2. Fogari R et al. _-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardivasc Pharmacol 1990; 16 (Suppl 5): S76
3.  Sponer G, Bartsch W, Strein K, Muller-Beckmann B, Bohm E. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol 1987; 9(3):317-327
4. Weber K, Bohmeke T, van der Does R, Taylor SH. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Cardiovasc Drugs Ther 1996;10(2):113-117
5. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126(12):955-959
6.  Hauf-Zachariou U, Widmann L, Zulsdorf B, Hennig M, Lang PD. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 1993; 45(2):95-100
7.  Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14(4):489-494
Lysko PG, Webb CL, Gu JL, Ohlstein EH, Ruffolo RR Jr, Yue TL. A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol 2000;36(2):277-281
8. Maggi E, Marchesi E, Covini D, Negro C, Perani G, Bellomo G. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996;27(4):532-538
9. Ohlstein EH, Douglas SA, Sung CP, Yue TL, Louden C, Arleth A, Poste G, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993;90(13):6189-6193
10. Yue TL. Antioxidant action of carvedilol. A potential role in treatment of heart failure. Heart Failure Reviews 1999;4:39-51
11.Stienen U, Meyer-Sabellek W. Hemodynamic and metabolic effects of carvedilol: a meta-analysis approach. Clin Invest 1992;70(Suppl 1):S65-S72
12. Goette D. Anwendungsbeobachtungen im Spannungsfeld von Wissenschaft und Marketing. Dtsch Med Wschr 2003;128:49-50
13. G.E. Shuetze, G.V. Sabin, I. Janitzki, A. Scherhag. Treatment of essential hypertension with Carvedilol: Results of the open-lable prospective trial in more then 10 000 patients. Perfusion 2003; 16:424-429
14.  George L. Bakris,  Vivian Fonseca, Richard E. Katholi at al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension. A Randomized Controlled Trial. JAMA, November 10, 2004-Vol 292, No. 18

В.Б.Мычка, И.Е.Чазова

Отдел системных гипертензий (рук. – д.м.н. И.Е.Чазова) Института клинической кардиологии им. А.Л.Мясникова (директор – акад. РАМН, член-корр. РАН Ю.Н.Беленков), Российский кардиологический научно-производственный комплекс (генеральный директор – академик РАН Е.И.Чазов) МЗ и СР РФ